| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ANAGENICS LIMITED: AGM Update | - | ASX | ||
| Do | ANAGENICS LIMITED: Notices under sections 203D and 249D of the Corporations Act | 1 | ASX | ||
| 15.11. | ANAGENICS LIMITED: Application for quotation of securities - AN1 | - | ASX | ||
| 12.11. | ANAGENICS LIMITED: Proposed issue of securities - AN1 | 1 | ASX | ||
| 11.11. | ANAGENICS LIMITED: Anagenics to Acquire Bio-First Skincare Brand | 1 | ASX | ||
| 05.11. | ANAGENICS LIMITED: Sale of Intellectual Property and Earn-Out Arrangement | 2 | ASX | ||
| ANAGENICS Aktie jetzt für 0€ handeln | |||||
| 04.11. | ANAGENICS LIMITED: Pause in Trading | - | ASX | ||
| 22.10. | ANAGENICS LIMITED: AN1 - Appendix 4C & Activity Report for Q1 FY2027 | - | ASX | ||
| 05.10. | ANAGENICS LIMITED: Notice of Annual General Meeting/Proxy Form | 2 | ASX | ||
| 28.08. | ANAGENICS LIMITED: AN1 - Appendix 4G JUN 2026 | - | ASX | ||
| 28.08. | ANAGENICS LIMITED: AN1 2026 Annual Report | - | ASX | ||
| 28.08. | ANAGENICS LIMITED: AN1 FY26-Appendix-4E- | - | ASX | ||
| 30.07. | ANAGENICS LIMITED: Appendix 4C & Activity Report for Q4 FY2026 | - | ASX | ||
| 27.07. | ANAGENICS LIMITED: Change of Auditor | - | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 34,485 | +0,13 % | 11 Milliarden US-Dollar für drei Fabriken: Warum Novo Nordisk den wahren Biotech-Engpass kauft | ||
| AURORA CANNABIS | 3,768 | -0,69 % | Das zwingt Anleger zum Handeln: Cannabisaktien am Wendepunkt: Warum Canopy, Tilray & Co. jetzt im Fokus stehen | © Foto: adobe.stock.comDie Quartalsberichte der Cannabis-Unternehmen boten Licht und Schatten - oder sollte man besser Hoffnung und Resignation sagen? Die Unterschiede hätten nicht größer sein können.... ► Artikel lesen | |
| CANOPY GROWTH | 0,400 | +1,16 % | Why Is Canopy Growth Stock Falling Friday? | ||
| TILRAY BRANDS | 1,710 | -0,58 % | Is Tilray a Buy at Its Record Low, or Is It a Value Trap? | ||
| VERTEX PHARMACEUTICALS | 468,75 | -0,26 % | Genomics Limited: Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals | Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals
The new agreement extends an existing 8-year collaboration between the companies OXFORD,... ► Artikel lesen | |
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,145 | 0,00 % | PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Arzneiwerk... ► Artikel lesen | |
| CRONOS GROUP | 2,790 | +0,14 % | Cronos Group Inc.: Cronos Group Reports 2026 Second Quarter Results | Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis... ► Artikel lesen | |
| DIGICANN VENTURES | 0,006 | 0,00 % | CSE Bulletin: Halted for Fundamental Change - Digicann Ventures Inc. (DCNN.X) | Le 6 novembre/November 2026
Trading in the shares of Digicann Ventures Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Change pursuant to... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,566 | +3,10 % | Organigram Global Inc: Organigram has 180 days to cure Nasdaq non-compliance | ||
| GREEN THUMB INDUSTRIES | 5,150 | +2,59 % | Green Thumb Has $316 Million in Cash, and Same-Store Sales Are Growing Again. Is It the Smartest Pot Stock to Buy? | ||
| IONIS PHARMACEUTICALS | 24,270 | 0,00 % | Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) | - TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG =880 mg/dL (=10 mmol/L) - - Approximately 700,000 people in the EU5 are estimated to have triglyceride... ► Artikel lesen | |
| NOVERIS HEALTH SCIENCES | 0,002 | -92,50 % | Noveris Health Sciences Inc.: Noveris Health Sciences Announces Commencement of Strategic Review Process | Vancouver, British Columbia--(Newsfile Corp. - November 13, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces that its board of directors... ► Artikel lesen | |
| SANTHERA PHARMACEUTICALS | 13,920 | +1,90 % | Santhera Pharmaceuticals Holding AG: Santhera unterzeichnet Vertriebsvereinbarung mit SteinCares für AGAMREE (Vamorolon) in 31 Ländern Lateinamerikas und der Karibik | Pratteln, Schweiz, 12. November 2026 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Unternehmen eine exklusive Vereinbarung mit SteinCares über den Vertrieb von AGAMREE (Vamorolon) zur... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 28,070 | +1,78 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen |